It recently announced a $30 million supply agreement with its partner RHEI Pharmaceuticals in China, a European launch with SpePharm, and a distribution deal with BioScrip in the US.

In conjunction with the $30 million supply agreement that roughly equates to Access' entire market capitalization, the company also approved a sub-license agreement between RHEI and Jian An Pharmaceuticals in Shenzhen, China, in an effort to leverage Jian An's sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan.

MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa, for the management of oral mucositis which is a side effect for cancer patients under radiation and chemotherapy

This morning, Access Pharma reported that two independent animal studies confirmed earlier findings that Cobalamin offers significant bioavailability of orally delivered insulin

Access is seeking to establish the product as the treatment-of-choice to prevent and treat oral mucositis. MuGard has already secured CE mark certification in Europe and is approved by the FDA

U.S. equity markets moved higher Tuesday afternoon as investors welcomed a report showing existing home sales surged in April for the first time since January.

U.S. equity markets looked set to open lower Tuesday after Fitch Ratings cut Japan’s credit rating, citing rising public debt and slow deficit-reduction efforts.

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.